165 related articles for article (PubMed ID: 7606203)
1. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview.
Kobayashi H; Matsunaga K; Oguchi Y
Cancer Epidemiol Biomarkers Prev; 1995; 4(3):275-81. PubMed ID: 7606203
[TBL] [Abstract][Full Text] [Related]
2. PSK as a chemopreventive agent.
Kobayashi H; Matsunaga K; Fujii M
Cancer Epidemiol Biomarkers Prev; 1993; 2(3):271-6. PubMed ID: 8318880
[TBL] [Abstract][Full Text] [Related]
3. Suppression of in vivo tumor-induced angiogenesis by the protein-bound polysaccharide PSK.
Kanoh T; Matsunaga K; Saito K; Fujii T
In Vivo; 1994; 8(2):247-50. PubMed ID: 7522606
[TBL] [Abstract][Full Text] [Related]
4. Antimetastatic effect of PSK, a protein-bound polysaccharide, against the B16-BL6 mouse melanoma.
Matsunaga K; Ohhara M; Oguchi Y; Iijima H; Kobayashi H
Invasion Metastasis; 1996; 16(1):27-38. PubMed ID: 8830763
[TBL] [Abstract][Full Text] [Related]
5. [Antitumor effect of intratumoral administration of a Coriolus preparation, PSK: inhibition of tumor invasion in vitro].
Ebina T; Murata K
Gan To Kagaku Ryoho; 1994 Sep; 21(13):2241-3. PubMed ID: 7944450
[TBL] [Abstract][Full Text] [Related]
6. Suppression of hepatic natural killer activity by liver metastasis of cancer and restoration of killer activity by oral administration of a Basidomycetes-derived polysaccharide, PSK.
Suo J; Tanaka N; Hizuta A; Yunoki S; Orita K
Acta Med Okayama; 1994 Oct; 48(5):237-42. PubMed ID: 7863794
[TBL] [Abstract][Full Text] [Related]
7. Restoration of immune responsiveness by a biological response modifier, PSK, in aged mice bearing syngeneic transplantable tumor.
Matsunaga K; Morita I; Oguchi Y; Fujii T; Yoshikumi C; Nomoto K
J Clin Lab Immunol; 1987 Nov; 24(3):143-9. PubMed ID: 3430562
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of the antitumor effect by the concurrent use of a monoclonal antibody and the protein-bound polysaccharide PSK in mice bearing a human cancer cell line.
Kanoh T; Saito K; Matsunaga K; Oguchi Y; Taniguchi N; Endoh H; Yoshimura M; Fujii T; Yoshikumi C
In Vivo; 1994; 8(2):241-5. PubMed ID: 7919129
[TBL] [Abstract][Full Text] [Related]
9. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy.
Fisher M; Yang LX
Anticancer Res; 2002; 22(3):1737-54. PubMed ID: 12168863
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of effector cell activities in mice bearing syngeneic plasmacytoma X5563 by a biological response modifier, PSK.
Matsunaga K; Iijima H; Aota M; Oguchi Y; Fujii T; Yoshikumi C; Nomoto K
J Clin Lab Immunol; 1992 Jan; 37(1):21-37. PubMed ID: 1339233
[TBL] [Abstract][Full Text] [Related]
11. Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs.
Zhang H; Morisaki T; Matsunaga H; Sato N; Uchiyama A; Hashizume K; Nagumo F; Tadano J; Katano M
Clin Exp Metastasis; 2000; 18(4):343-52. PubMed ID: 11448066
[TBL] [Abstract][Full Text] [Related]
12. The role of neutrophils as cytotoxic cells in lung metastasis: suppression of tumor cell metastasis by a biological response modifier (PSK).
Ishihara Y; Fujii T; Iijima H; Saito K; Matsunaga K
In Vivo; 1998; 12(2):175-82. PubMed ID: 9627799
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of PSK at a distant site: tumor-specific immunity and combination with other chemotherapeutic agents.
Ebina T; Murata K
Jpn J Cancer Res; 1992 Jul; 83(7):775-82. PubMed ID: 1517151
[TBL] [Abstract][Full Text] [Related]
14. Competitive action of a biological response modifier, PSK, on a humoral immunosuppressive factor produced in tumor-bearing hosts.
Matsunaga K; Morita I; Iijima H; Endo H; Oguchi Y; Yoshimura M; Fujii T; Yoshikumi C; Nomoto K
J Clin Lab Immunol; 1990 Mar; 31(3):127-36. PubMed ID: 1966997
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of interferon-gamma-induced human myelogenous leukemic cell differentiation by high molecular weight PSK subfraction.
Kim F; Sakagami H; Tanuma S; Konno K
Anticancer Res; 1990; 10(1):55-8. PubMed ID: 2110432
[TBL] [Abstract][Full Text] [Related]
16. Effect of Krestin (PSK) on the induction of IL-2 activated killer cells.
Sakamaki S; Kohgo Y; Nojiri S; Kanisawa Y; Ito Y; Takahashi M; Ueno Y; Hirayama Y; Niitsu Y
Jpn J Clin Oncol; 1992 Apr; 22(2):79-83. PubMed ID: 1619782
[TBL] [Abstract][Full Text] [Related]
17. Protein-bound polysaccharide K reduced the invasive ability of colon cancer cell lines.
Uwafuji S; Goi T; Naruse T; Kurebayashi H; Nakazawa T; Hirono Y; Yamaguchi A
Anticancer Res; 2013 Nov; 33(11):4841-5. PubMed ID: 24222121
[TBL] [Abstract][Full Text] [Related]
18. Effects of biological response modifiers with different modes of action used separately and together on immune responses in mice with syngeneic tumours.
Matsunaga K; Morita I; Iijima H; Endoh H; Oguchi Y; Yoshimura M; Fujii T; Yoshikumi C; Nomoto K
J Int Med Res; 1992 Sep; 20(5):406-21. PubMed ID: 1280606
[TBL] [Abstract][Full Text] [Related]
19. Prolongation of the survival period with the biological response modifier PSK in rats bearing N-methyl-N-nitrosourea-induced mammary gland tumors.
Fujii T; Saito K; Matsunaga K; Oguchi Y; Ikuzawa M; Furusho T; Taguchi T
In Vivo; 1995; 9(1):55-7. PubMed ID: 7669949
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice.
Harada M; Matsunaga K; Oguchi Y; Iijima H; Tamada K; Abe K; Takenoyama M; Ito O; Kimura G; Nomoto K
Int J Cancer; 1997 Jan; 70(3):362-72. PubMed ID: 9033641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
